"We believe that the full potential of our H1N1 vaccine business has yet to be realized in our stock price and this report outlines some of the issues involved," said HTDS CEO Terry Yuan. "Take a good look at all that is going on now for HTDS and you may be surprised to find that when you do so, you share our enthusiasm for HTDS. H1N1 is done and completed so we are eager to start to profit from this huge demand from customers who want to now buy HTDS products immediately. We are also moving with great energy to get our audits completed and get OTCBB listed. When you look at the potential cancer and anti-aging projects of Slavica Bio Chem it is easy to find yourself strongly visualizing their enormous potential. HTDS is also taking aggressive action against the suspected naked shorting that has apparently affected our stock so we can remove all possible barriers to appreciation and give our investors confidence in the future of their investment.

Further, most people do not seem to realize we have recently made a sizable recent reduction in our stock outstanding and understand fully what that means. When you add all the excitement all this has created to our eagerness to move forward, it can cause you to start to see that we are on verge of a major expansion. We believe you have to find yourself putting HTDS in that spot in your mind where you would put a company that has virtually unlimited upside. We look forward to the future and we believe that a year from now we will find ourselves looking back on back on this time as one where we all participated in a major expansion."

SOURCE Hard to Treat Diseases